BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 16812953)

  • 1. Prevention of iatrogenic transmission of B19 infection: different approaches to detect, remove or inactivate virus contamination.
    Bonvicini F; Gallinella G; Gentilomi GA; Ambretti S; Musiani M; Zerbini M
    Clin Lab; 2006; 52(5-6):263-8. PubMed ID: 16812953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety issues for plasma derivatives and benefit from NAT testing.
    Willkommen H; Schmidt I; Löwer J
    Biologicals; 1999 Dec; 27(4):325-31. PubMed ID: 10686059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma.
    Baylis SA; Shah N; Minor PD
    J Virol Methods; 2004 Oct; 121(1):7-16. PubMed ID: 15350727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular testing for detection of in vitro infectivity of plasma pools contaminated with B19 virus.
    Bonvicini F; Gallinella G; Cricca M; Ambretti S; Delbarba S; Musiani M; Zerbini M
    J Med Virol; 2004 Oct; 74(2):272-6. PubMed ID: 15332276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparations.
    Yunoki M; Urayama T; Tsujikawa M; Sasaki Y; Abe S; Takechi K; Ikuta K
    Br J Haematol; 2005 Feb; 128(3):401-4. PubMed ID: 15667545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing the risk of infection from plasma products: specific preventative strategies.
    Burnouf T; Radosevich M
    Blood Rev; 2000 Jun; 14(2):94-110. PubMed ID: 11012252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
    Nübling CM; Unkelbach U; Chudy M; Seitz R
    Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability of parvovirus B19 to inactivation by liquid heating in plasma products.
    Hattori S; Yunoki M; Tsujikawa M; Urayama T; Tachibana Y; Yamamoto I; Yamamoto S; Ikuta K
    Vox Sang; 2007 Feb; 92(2):121-4. PubMed ID: 17298573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of B19 parvovirus in plasma pools before solvent-detergent treatment of plasma: AFSSAPS and EFS Aquitaine-Limousin's experience].
    Petermann R; Piquet Y; Lapeyre M; Goujon N; Gauthier M; Lalanne V; Mouillot L; Tissier MH; Boiron JM
    Transfus Clin Biol; 2010 Apr; 17(2):54-62. PubMed ID: 20674438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates.
    Modrow S; Wenzel JJ; Schimanski S; Schwarzbeck J; Rothe U; Oldenburg J; Jilg W; Eis-Hübinger AM
    Vox Sang; 2011 May; 100(4):351-8. PubMed ID: 21133933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay.
    Kleinman SH; Glynn SA; Lee TH; Tobler L; Montalvo L; Todd D; Kiss JE; Shyamala V; Busch MP;
    Transfusion; 2007 Oct; 47(10):1756-64. PubMed ID: 17880600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing.
    Geng Y; Wu CG; Bhattacharyya SP; Tan D; Guo ZP; Yu MY
    Transfusion; 2007 May; 47(5):883-9. PubMed ID: 17465954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Safety of blood products and B19 parvovirus].
    Lefrère JJ; Maniez-Montreuil M; Morel P; Defer C; Laperche S
    Transfus Clin Biol; 2006 Oct; 13(4):235-41. PubMed ID: 16822687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variants of B19.
    Brown KE
    Dev Biol (Basel); 2004; 118():71-7. PubMed ID: 15645675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a new LightCycler reverse transcription-polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry-heat inactivation studies.
    Prikhod'ko GG; Vasilyeva I; Reyes H; Wong S; Brown KE; Jameson T; Busby TF
    Transfusion; 2005 Jun; 45(6):1011-9. PubMed ID: 15935001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of Parvovirus B19 and Hepatitis A virus in Portuguese blood donors.
    Henriques I; Monteiro F; Meireles E; Cruz A; Tavares G; Ferreira M; Araújo F
    Transfus Apher Sci; 2005 Nov; 33(3):305-9. PubMed ID: 16203176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parvovirus B19 transmission by a high-purity factor VIII concentrate.
    Wu CG; Mason B; Jong J; Erdman D; McKernan L; Oakley M; Soucie M; Evatt B; Yu MY
    Transfusion; 2005 Jun; 45(6):1003-10. PubMed ID: 15935000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Viral safety in hemotherapy. Current aspects of hepatitis C and parvovirus B19 detection for plasma component therapy].
    Sibrowski W; Kühnl P
    Beitr Infusionsther; 1990; 26():22-6. PubMed ID: 1703836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human erythrovirus B19 and blood transfusion - an update.
    Parsyan A; Candotti D
    Transfus Med; 2007 Aug; 17(4):263-78. PubMed ID: 17680952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
    Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
    Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.